



David Iberri

Clinical Associate Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Stanford Medicine Hematology Clinic**

875 Blake Wilbur Dr

3rd Fl

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 724-5203

Bio

BIO

Dr. Iberri is a hematologist who specializes in the treatment of multiple myeloma, Waldenström macroglobulinemia, and other blood and bone marrow disorders. He is actively involved in clinical research evaluating novel agents in hematologic malignancies. His research interests include the development and application of biomarkers to select patients most likely to benefit from therapy, and in the development of blood tests to reduce the need for bone marrow biopsies in myeloma disease monitoring.

CLINICAL FOCUS

- Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Polycythemia Vera
- Essential Thrombocythemia
- Myeloproliferative Disorders
- Iron Deficiency Anemia
- Venous Thromboembolism
- Aplastic Anemia
- Hematology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Hematology

ADMINISTRATIVE APPOINTMENTS

- Member, Stanford Professional Practice Evaluation Committee, (2016- present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2015) CA
- Residency: Stanford University Internal Medicine Residency (2013) CA
- Internship: Stanford University Internal Medicine Residency (2011) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Medical Education: University of Vermont College of Medicine (2010) VT

Research & Scholarship

CLINICAL TRIALS

- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment, Recruiting
- A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence, Not Recruiting
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy, Not Recruiting
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL, Not Recruiting
- Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML, Not Recruiting
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL), Not Recruiting
- Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL, Not Recruiting
- Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Hematology (Fellowship Program)
- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **MGCS: where do we stand today?** *Hematology. American Society of Hematology. Education Program*
Iberri, D., Liedtke, M.
2024; 2024 (1): 482-488
- **Clonality Determination by Detecting Unmodified Monoclonal Serum Free Light Chains Using On-Probe Extraction Coupled with Liquid Chromatography-High-Resolution Mass Spectrometry.** *Clinical chemistry*
Yeung, P. S., Liu, Y., Yang, S., Ruan, A., Kerr, C. R., Wong, C. V., Shi, R. Z., Iberri, D. J., Luo, R. Y.
2024
- **Safety of subcutaneous daratumumab in the treatment of plasma-cell disorders: A single-center experience.**
Kye, J., Seyer, M., Patel, S., Kim, E., Hewitt, R., Liedtke, M., Iberri, D.

LIPPINCOTT WILLIAMS & WILKINS.2021

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Monoclonal versus monotypic: promoting awareness of terminology and clinical take-aways.** *Kidney international*
Zheng, S., Iberri, D. J., Ziolkowski, S.
2026; 109 (3): 609-610
- **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
- **Real time machine learning prediction of next generation sequencing test results in live clinical settings.** *NPJ digital medicine*
Kim, G. Y., Schwede, M., Corbin, C. K., Fouladvand, S., Brar, R., Iberri, D., Shomali, W., Oak, J. S., Gratzinger, D., Stehr, H., Chen, J. H.
2025; 8 (1): 533
- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
2025; 16 (1): 1824
- **Bilateral retinal vasculitis associated with cold agglutinin disease treated with obinutuzumab and infliximab.** *American journal of ophthalmology case reports*
Than, N. T., Yaşar, Ç., Pham, B. H., Lam, B. C., Doan, H. L., Akhavanrezayat, A., Halim, M. S., Iberri, D. J., Hien, D. L., Dong Nguyen, Q.
2022; 28: 101752
- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
AMER SOC HEMATOLOGY.2022: 1546-1548
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Machine Learning Predictability of Clinical Next Generation Sequencing for Hematologic Malignancies to Guide High-Value Precision Medicine.** *AMIA ... Annual Symposium proceedings. AMIA Symposium*
Kim, G. Y., Noshad, M., Stehr, H., Rojansky, R., Gratzinger, D., Oak, J., Brar, R., Iberri, D., Kong, C., Zehnder, J., Chen, J. H.
2021; 2021: 641-650
- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*

Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al

2020

- **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*
Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gotlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
2020: 1–8
- **Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.** *Surgery open science*
Alobuia, W. M., Perrone, K. n., Iberri, D. J., Brar, R. S., Spain, D. A., Forrester, J. D.
2020; 2 (4): 19–24
- **Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors** *AMERICAN JOURNAL OF HEMATOLOGY*
Leaf, R., Ferreri, C., Rangachari, D., Mier, J., Witteles, W., Ansstas, G., Anagnostou, T., Zubiri, L., Piotrowska, Z., Oo, T. H., Iberri, D., Yarchoan, M., Salama, et al
2019; 94 (5): 563–74
- **Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors.** *American journal of hematology*
Leaf, R. K., Ferreri, C., Rangachari, D., Mier, J., Witteles, W., Ansstas, G., Anagnostou, T., Zubiri, L., Piotrowska, Z., Oo, T. H., Iberri, D., Yarchoan, M., Salama, et al
2019
- **Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia**
Garcia, J. S., Bhatt, S., Fell, G., Blonquist, T. M., Taw, J., Iberri, D., Letai, A., Medeiros, B. C.
AMER SOC HEMATOLOGY.2018
- **Postibrutinib outcomes in patients with mantle cell lymphoma** *BLOOD*
Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., Spurgeon, S., Kozin, E., Noto, et al
2016; 127 (12): 1559-1563
- **Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.** *British journal of haematology*
2016
- **Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management**
Iberri, D. J., Kwong, B., Stevens, L., Coutre, S. E., Kim, J., Sabile, J., Advani, R. H.
AMER SOC HEMATOLOGY.2015
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*
Iberri, D. J., Colevas, A. D.
2015; 20 (12): 1393-1403
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.** *The oncologist*
Iberri, D. J., Colevas, A. D.
2015
- **Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.** *Current treatment options in oncology*
Iberri, D. J., Hoppe, R. T., Advani, R. H.
2015; 16 (9): 45-?
- **Building a Modern Journal Club: The Wiki Journal Club Experience.** *Journal of graduate medical education*
Plante, T. B., Iberri, D. J., Coderre, E. L.
2015; 7 (3): 341-3

- **Clinical Evidence Summary Apps: Definition, Role, and Unknowns About a Novel Medical Content Delivery Genre.** *Journal of graduate medical education*
Plante, T. B., Kane, S. P., Iberri, D. J., Majure, D. T.
2014; 6 (4): 791-?
- **Clinicopathologic Characteristics of HER2 FISH-ambiguous Breast Cancer at a Single Institution** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*
Clay, M. R., Iberri, D. J., Bangs, C. D., Cherry, A., Jensen, K. C.
2013; 37 (1): 120-127
- **Wikipedia: A Key Tool for Global Public Health Promotion** *JOURNAL OF MEDICAL INTERNET RESEARCH*
Heilman, J. M., Kemmann, E., Bonert, M., Chatterjee, A., Ragar, B., Beards, G. M., Iberri, D. J., Harvey, M., Thomas, B., Stomp, W., Martone, M. F., Lodge, D. J., Vondracek, et al
2011; 13 (1): 153-164